View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
April 27, 2020updated 22 Nov 2021 6:14am

ARDS treatments are important for severe Covid-19

By GlobalData Healthcare

The Covid-19 pandemic continues to spread, now reaching over 2.7 million cases with over 193,000 deaths. Pharmaceutical companies continue their work on finding treatments to lessen the symptoms of the disease and improve the survival of the most severely affected patients. Several drugs are under investigation for their ability to reduce acute respiratory distress syndrome (ARDS), a cause of death in Covid-19 patients.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

In some Covid-19 patients, the virus triggers a severe immune response in their lungs. This causes the production of inflammatory molecules called cytokines, which results in a “cytokine storm.” The lungs fill with water and become impermeable to oxygen, causing even mechanical ventilation to fail to rescue these patients.

Treatment for acute respiratory distress syndrome for the severely affected portion of the Covid-19 patients will play an important role in decreasing the mortality of the disease. About one in six Covid-19 patients have difficulty breathing, and about 40% of those with difficulty breathing develop ARDS. Of ARDS patients, who are treated with mechanical ventilation, there is a 20–50% survival rate. The estimated mortality rate is 80% for moderate to severe Covid-19-related ARDS.

Researchers are investigating several drugs for their ability to treat Covid-19-triggered ARDS. Relief Therapeutic has initiated a clinical trial of its aviptadil at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, US for the treatment of ARDS in Covid-19 patients. This drug has a naturally synthesised peptide that is 40% concentrated in the lungs. This peptide been shown to have potent anti-cytokine activity and has been safely used for 20 years to treat other diseases in humans.

Another drug being investigated to treat ARDS in Covid-19 patients is Mesoblast Limited’s drug remestemcel-L. It was developed for other inflammatory conditions and down-regulates the production of pro-inflammatory cytokines while up-regulating anti-inflammatory cytokines and cells.

Hospitals and ventilator usage in intensive care units are already being taxed by Covid-19 ARDS patients. Finding treatments that will lessen these demands will improve patient outcomes and free up resources to help other patients. Repurposing already-available drugs could shorten the time to these treatments being approved.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU